Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals

Julieta Trinks1 Basic Science and Experimental Medicine Institute (ICBME), University Institute of the Italian Hospital of Buenos Aires;2 Scientific and Technological National Research Council (CONICET)Correspondence[email protected]

Mariela Caputo2 Scientific and Technological National Research Council (CONICET);3 Servicio de Huellas Digitales Genéticas, Facultad de Farmacia y Bioquímica

María L Hulaniuk1 Basic Science and Experimental Medicine Institute (ICBME), University Institute of the Italian Hospital of Buenos Aires

Daniel Corach2 Scientific and Technological National Research Council (CONICET);3 Servicio de Huellas Digitales Genéticas, Facultad de Farmacia y Bioquímica

Diego Flichman2 Scientific and Technological National Research Council (CONICET);4 Cátedra de Virología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals

Articles from other publishers (3)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals

Citations (3)

Articles from other publishers (3)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date